A detailed history of National Asset Management, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, National Asset Management, Inc. holds 163,095 shares of BMY stock, worth $8.3 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares
163,095
Previous 185,863 12.25%
Holding current value
$8.3 Million
Previous $10.1 Million 32.8%
% of portfolio
0.18%
Previous 0.23%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 19, 2024

SELL
$40.25 - $52.99 $916,412 - $1.21 Million
-22,768 Reduced 12.25%
163,095 $6.77 Million
Q1 2024

May 16, 2024

BUY
$47.98 - $54.4 $1.08 Million - $1.22 Million
22,462 Added 13.75%
185,863 $10.1 Million
Q4 2023

Mar 15, 2024

SELL
$48.48 - $57.85 $1.09 Million - $1.3 Million
-22,462 Reduced 12.09%
163,401 $8.38 Million
Q3 2023

Dec 01, 2023

SELL
$57.89 - $64.73 $15.1 Million - $16.9 Million
-261,399 Reduced 58.44%
185,863 $10.8 Million
Q2 2023

Jul 27, 2023

BUY
$63.71 - $70.74 $14.8 Million - $16.4 Million
232,490 Added 108.25%
447,262 $28.6 Million
Q1 2023

May 17, 2023

BUY
$65.71 - $74.53 $242,075 - $274,568
3,684 Added 1.75%
214,772 $14.9 Million
Q4 2022

Mar 15, 2023

SELL
$68.48 - $81.09 $213,931 - $253,325
-3,124 Reduced 1.46%
211,088 $15.2 Million
Q4 2022

Feb 21, 2023

BUY
$68.48 - $81.09 $1.01 Million - $1.19 Million
14,701 Added 7.37%
214,212 $15.4 Million
Q3 2022

Nov 14, 2022

BUY
$0.13 - $76.84 $10,482 - $6.2 Million
80,637 Added 67.83%
199,511 $14.2 Million
Q2 2022

Aug 12, 2022

SELL
$72.62 - $79.98 $1.09 Million - $1.2 Million
-14,987 Reduced 11.2%
118,874 $9.15 Million
Q1 2022

May 02, 2022

SELL
$61.48 - $73.72 $274,139 - $328,717
-4,459 Reduced 3.22%
133,861 $9.78 Million
Q4 2021

Jan 28, 2022

SELL
$53.63 - $62.52 $36,736 - $42,826
-685 Reduced 0.49%
138,320 $8.63 Million
Q3 2021

Nov 16, 2021

BUY
$59.17 - $69.31 $408,864 - $478,932
6,910 Added 5.23%
139,005 $8.26 Million
Q2 2021

Aug 10, 2021

BUY
$61.91 - $67.42 $722,056 - $786,319
11,663 Added 9.68%
132,095 $8.81 Million
Q1 2021

May 13, 2021

BUY
$59.34 - $66.74 $1.51 Million - $1.7 Million
25,509 Added 26.87%
120,432 $7.6 Million
Q4 2020

Feb 04, 2021

SELL
$57.74 - $65.43 $1.44 Million - $1.63 Million
-24,930 Reduced 20.8%
94,923 $5.89 Million
Q3 2020

Nov 09, 2020

BUY
$57.43 - $63.64 $2.07 Million - $2.29 Million
35,976 Added 42.89%
119,853 $7.19 Million
Q2 2020

Jul 31, 2020

BUY
$54.82 - $64.09 $364,936 - $426,647
6,657 Added 8.62%
83,877 $4.93 Million
Q1 2020

May 06, 2020

BUY
$46.4 - $67.43 $330,368 - $480,101
7,120 Added 10.16%
77,220 $4.31 Million
Q4 2019

Feb 10, 2020

BUY
$49.21 - $64.19 $1.47 Million - $1.92 Million
29,865 Added 74.23%
70,100 $4.46 Million
Q3 2019

Nov 12, 2019

BUY
$42.77 - $50.71 $769 - $912
18 Added 0.04%
40,235 $2.04 Million
Q2 2019

Aug 05, 2019

BUY
$44.62 - $49.34 $158,177 - $174,910
3,545 Added 9.67%
40,217 $1.83 Million
Q1 2019

May 08, 2019

BUY
$45.12 - $53.8 $91,593 - $109,214
2,030 Added 5.86%
36,672 $1.77 Million
Q4 2018

Feb 08, 2019

SELL
$48.76 - $63.23 $190,017 - $246,407
-3,897 Reduced 10.11%
34,642 $1.8 Million
Q3 2018

Nov 08, 2018

BUY
$55.19 - $62.25 $25,552 - $28,821
463 Added 1.22%
38,539 $2.4 Million
Q2 2018

Oct 05, 2018

SELL
$50.53 - $62.98 $286,404 - $356,970
-5,668 Reduced 12.96%
38,076 $2.11 Million
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $1.33 Million - $1.53 Million
-22,183 Reduced 33.65%
43,744 $2.77 Million
Q4 2017

Feb 15, 2018

BUY
$59.94 - $65.35 $66,233 - $72,211
1,105 Added 1.7%
65,927 $4.04 Million
Q3 2017

Nov 13, 2017

SELL
$55.23 - $63.74 $55,230 - $63,740
-1,000 Reduced 1.52%
64,822 $4.14 Million
Q2 2017

Aug 15, 2017

BUY
N/A
65,822
65,822 $3.67 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $108B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track National Asset Management, Inc. Portfolio

Follow National Asset Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Asset Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on National Asset Management, Inc. with notifications on news.